Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenfluramine for Rett syndrome phase 3 trial with open-label extension
2025-523157-34-00Phase 3Authorised
- Sponsor
- UCB
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of fenfluramine in Rett syndrome (RTT) (3 arms), sponsored by UCB. Primary endpoints: Change from baseline to Week 14 in Rett Syndrome Behaviour Questionnaire total score and Clinical Global Impression of Change score. Planned start Jul 2026; status: authorised.
02
Drugs
fenfluramine
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on 2025-523157-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523157-34-00.